United States· US:0597-0385_ca86ce8b-9c04-47d8-94e3-ae041f251fab
Trijardy XR
A metformin, linagliptin and empagliflozin product containing empagliflozin; linagliptin; metformin hydrochloride, registered in United States by Boehringer Ingelheim Pharmaceuticals, Inc..
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE
- Manufacturer
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Country
- United States (US)
- ATC code
- A10BD27
- ATC class
- Metformin, linagliptin and empagliflozin
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- August 23, 2026
Packs & prices · 4
- ndc11059703857760 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0385-77)
- ndc110597038586180 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0385-86)
- ndc110597-0385-77
- ndc110597-0385-86
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under A10BD27
Metformin, linagliptin and empagliflozin, as other registers publish it.
- United StatesTrijardy XRBoehringer Ingelheim Pharmaceuticals, Inc.
- United StatesTrijardy XRBoehringer Ingelheim Pharmaceuticals, Inc.
- United StatesTrijardy XRBoehringer Ingelheim Pharmaceuticals, Inc.
- United StatesTrijardy XRBoehringer Ingelheim Pharmaceuticals, Inc.
- United StatesTrijardy XRBoehringer Ingelheim Pharmaceuticals, Inc.
- United StatesTrijardy XRBoehringer Ingelheim Pharmaceuticals, Inc.
- United StatesTrijardy XRBoehringer Ingelheim Pharmaceuticals, Inc.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bd01cb11-e675-4c1f-ac90-92f454c152fe GET /v1/drugs/bd01cb11-e675-4c1f-ac90-92f454c152fe?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "12.5; 2.5; 1000",
"substance": "EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE",
"productndc": "0597-0385",
"dosage_form": "TABLET, EXTENDED RELEASE",
"dea_schedule": null,
"strength_unit": "mg/1; mg/1; mg/1",
"application_number": "NDA212614",
"marketing_category": "NDA"
}See everything about metformin, linagliptin and empagliflozin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.